This executive order recites the burden of suicide and serious mental illnesses in the United States and the fact that psychedelic drugs, including ibogaine, have shown potential in critical studies to address mental illness for patients whose conditions persist after completing standard therapy and that the FDA has granted breakthrough therapy designation (increases patient access to therapies) to specific psychedelic drugs. It directs the commissioner of food and drugs to provide commissioner’s national priority vouchers to appropriate psychedelic drugs that have received a breakthrough therapy designation and the FDA and DEA to facilitate and establish a pathway for eligible patients to access psychedelic drugs. It also directs the secretary of health and human services to allocate at least $50 million from existing funds to support and partner with state governments that have enacted or are developing programs to advance psychedelic drugs for serious mental illnesses. Finally, it directs the Department of Health and Human Services and the FDA to collaborate with the Department of Veterans Affairs to increase clinical trial participation, data sharing and real-world evidence generation regarding psychedelic drug therapy.